Skip to main content
Figure 2 | European Journal of Medical Research

Figure 2

From: New hepatitis C therapies in clinical development

Figure 2

A) SPRINT-2 treatment arms in treatment-naïve patients with HCV genotype 1 were as follows: (i) 4-week lead-in with PEG-IFN alfa-2b plus ribavirin (PR) followed by 44 weeks of PR plus boceprevir (B); (ii) 4-week lead-in with PR followed by PR plus B for 24 weeks or followed by PR plus B for 24 weeks and PR for additional 20 weeks, based on treatment response at week 8 and 12; (iii) PR alone for 48 weeks. B) The RESPOND-2 treatment schedule, conducted in treatment-experienced patients with HCV genotype 1 was as follows: (i) 4-week lead-in with PR followed by PR plus B for 44 weeks, (ii) 4-week lead in with PR followed by PR plus B for 32 weeks or followed by PR plus B for 32 weeks and PR for additional 12 weeks, based on treatment response at week 8 and 12; (iii) PR alone for 48 weeks. **eRVR defined as HCV RNA negativity at week 8 through 24; ***in the SRINT-2 control arm, only standard RVR data (negative HCV RNA at week 8) are shown. ERVR results were not available at the time of submission of this manuscript.

Back to article page